• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新冠病毒感染期间中等及大动脉血栓形成:COVIVASC 研究结果。

Thrombosis of Medium-Sized and Large Arteries During Covid-19 Infection: Results of the COVIVASC Study.

机构信息

Department of Vascular Surgery, Ambroise Paré University Hospital, Assistance Publique-Hôpitaux de Paris, 92104 Boulogne-Billancourt, France; UMR 1018, Inserm-Paris11 - CESP, Versailles Saint-Quentin-en-Yvelines University, Paris-Saclay University, Paul Brousse Hospital, 94807 Villejuif, France.

Department of Vascular Surgery, Ambroise Paré University Hospital, Assistance Publique-Hôpitaux de Paris, 92104 Boulogne-Billancourt, France; UMR 1018, Inserm-Paris11 - CESP, Versailles Saint-Quentin-en-Yvelines University, Paris-Saclay University, Paul Brousse Hospital, 94807 Villejuif, France.

出版信息

Ann Vasc Surg. 2022 Oct;86:35-42. doi: 10.1016/j.avsg.2022.04.055. Epub 2022 Jun 30.

DOI:10.1016/j.avsg.2022.04.055
PMID:35780947
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9242891/
Abstract

BACKGROUND

COVID-19 infection is associated not only with venous thromboses but also with arterial thromboses (COV-ATs) in relation with an endothelial dysfunction, a coagulopathy and rhythm disorders. The incidence, the topography, and the prognosis of COV-ATs remain poorly known. The objective of this study was to report the overall experience of the Greater Paris University Hospitals (Assistance Publique - Hopitaux de Paris, AP-HP) during the first pandemic wave of COVID-19 infection.

METHODS

After approval by the ethics committee, a study using the AP-HP clinical data warehouse was carried out between March and May 2020. Overall, 124,609 patients had a polymerase chain reaction for COVID-19 in our hospitals, of which 25,345 were positive. From 20,710 exploitable stays, patients tested positive for COVID who presented an episode of acute COV-AT (except coronary and intracranial arteries) were selected on the basis of the French medical classification for clinical procedures codes. The data are presented as absolute values with percentages and/or means with standard deviation.

RESULTS

Over the studied period, 60 patients (aged 71±14 years, 42 men) presented a COV-AT at the time of their hospitalization, an incidence of 0.2%. The arterial complication occurred 3±7 days after the COVID infection and was inaugural in 30% of the cases (n = 18). The sites of COV-AT were the lower extremities (n = 35%, 58%), the abdominal aorta (n = 10%, 17%), the thoracic aorta (n = 7%, 12%), the upper limbs (n = 7%, 12%), the cerebral arteries (n = 7%, 12%), the digestive arteries (n = 6%, 10%), the renal arteries (n = 2%, 3%), and the ophthalmic artery (n = 1%, 2%). Multiple COV-ATs were observed in 13 patients (22%). At the time of diagnosis, 20 (33%) patients were in intensive care, including six (10%) patients who were intubated. On computed tomography angiography, COVID lesions were classified as moderate and severe in 25 (42%) and 21 (35%) cases, respectively. Revascularization was attempted in 27 patients (45%), by open surgery in 16 cases, using endovascular techniques in 8 cases and with a hybrid approach in three cases. Six patients (22%) required reinterventions. The duration of hospitalization was 12±9 days. Early mortality (in-hospital or at 30 days) was 30% (n = 18). Nine (15%) patients presented severe nonlethal ischemic complications.

CONCLUSIONS

Arterial involvement is rare during COVID-19 infection. The aorta and the arteries of the limbs are the privileged sites. The morbi-mortality of these patients is high. Future studies will have to determine if the systematization of anticoagulation therapy decreases the incidence and the severity of the condition.

摘要

背景

COVID-19 感染不仅与静脉血栓形成有关,还与内皮功能障碍、凝血功能障碍和节律紊乱有关的动脉血栓形成(COV-ATs)有关。COV-ATs 的发生率、病变部位和预后仍知之甚少。本研究的目的是报告巴黎大区公立医院(巴黎公立医院集团,AP-HP)在 COVID-19 感染第一波大流行期间的总体经验。

方法

在伦理委员会批准后,于 2020 年 3 月至 5 月期间使用 AP-HP 临床数据仓库进行了一项研究。在我们的医院中,共有 124609 名患者进行了 COVID-19 的聚合酶链反应检测,其中 25345 名呈阳性。从 20710 个可利用的住院患者中,根据法国医疗分类临床程序代码,选择了在 COVID 检测呈阳性并出现急性 COV-AT(不包括冠状动脉和颅内动脉)的患者。数据以绝对值和百分比表示,或平均值和标准差表示。

结果

在研究期间,60 名患者(年龄 71±14 岁,42 名男性)在住院期间发生了 COV-AT,发病率为 0.2%。动脉并发症发生在 COVID 感染后 3±7 天,首发于 30%的病例(n=18)。COV-AT 的部位为下肢(n=35%,58%)、腹主动脉(n=10%,17%)、胸主动脉(n=7%,12%)、上肢(n=7%,12%)、脑动脉(n=7%,12%)、消化道动脉(n=6%,10%)、肾动脉(n=2%,3%)和眼动脉(n=1%,2%)。13 名患者(22%)有多处 COV-AT。诊断时,20 名(33%)患者在重症监护病房,包括 6 名(10%)需要插管的患者。在计算机断层血管造影(CTA)上,COVID 病变分别在 25 名(42%)和 21 名(35%)患者中被归类为中度和重度。对 27 名患者(45%)进行了血运重建,其中 16 名采用开放手术,8 名采用血管内技术,3 名采用混合方法。6 名患者(22%)需要再次介入。住院时间为 12±9 天。早期死亡率(住院或 30 天内)为 30%(n=18)。9 名(15%)患者出现严重非致死性缺血性并发症。

结论

COVID-19 感染期间动脉受累罕见。主动脉和四肢动脉是其主要受累部位。这些患者的病死率较高。未来的研究将不得不确定抗凝治疗的系统化是否会降低疾病的发生率和严重程度。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6b2/9242891/abce074a3103/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6b2/9242891/abce074a3103/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6b2/9242891/abce074a3103/gr1_lrg.jpg

相似文献

1
Thrombosis of Medium-Sized and Large Arteries During Covid-19 Infection: Results of the COVIVASC Study.新冠病毒感染期间中等及大动脉血栓形成:COVIVASC 研究结果。
Ann Vasc Surg. 2022 Oct;86:35-42. doi: 10.1016/j.avsg.2022.04.055. Epub 2022 Jun 30.
2
Analysis of the impact of the SARS-CoV-2 infection on the pediatric population hospitalized during the pandemic in the Greater Paris University Hospitals.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染对大巴黎大学医院疫情期间住院儿童人群影响的分析。
Front Pediatr. 2023 Feb 27;11:1044352. doi: 10.3389/fped.2023.1044352. eCollection 2023.
3
Intensive care for seriously ill patients affected by novel coronavirus sars - CoV - 2: Experience of the Crema Hospital, Italy.重症监护治疗新型冠状病毒 SARS-CoV-2 感染患者:意大利克雷马医院的经验。
Am J Emerg Med. 2021 Jul;45:156-161. doi: 10.1016/j.ajem.2020.08.005. Epub 2020 Aug 16.
4
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
5
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
6
Early experience with arterial thromboembolic complications in patients with COVID-19.COVID-19 患者动脉血栓栓塞并发症的早期经验。
J Vasc Surg. 2021 Feb;73(2):381-389.e1. doi: 10.1016/j.jvs.2020.07.089. Epub 2020 Aug 28.
7
A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.一项评估静脉注射瑞维鲁单抗对比 COVID-19 重症肺炎、急性肺损伤或急性呼吸窘迫综合征患者最佳支持治疗的疗效和安全性的 III 期开放性标签、随机对照研究:一项随机对照试验研究方案的结构性总结。
Trials. 2020 Jul 13;21(1):639. doi: 10.1186/s13063-020-04548-z.
8
Aortic thrombosis as a dramatic vascular complication in COVID-19 disease.COVID-19 疾病中的主动脉血栓形成:一种戏剧性的血管并发症。
J Med Vasc. 2022 Oct;47(4):169-174. doi: 10.1016/j.jdmv.2022.10.003. Epub 2022 Oct 11.
9
Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.恢复期血浆/甲磺酸卡莫司他用于早期SARS-CoV-2 Q-PCR阳性高危个体(RES-Q-HR):一项随机对照试验研究方案的结构化总结
Trials. 2021 May 17;22(1):343. doi: 10.1186/s13063-021-05181-0.
10
Evaluation of the prevalence of new-onset musculoskeletal symptoms in patients hospitalized for severe SARS-CoV-2 infection during the first two COVID waves in France: A descriptive analysis of the clinical data warehouse of 39 hospitals in France.评估法国前两波 COVID 期间因严重 SARS-CoV-2 感染住院患者新发肌肉骨骼症状的患病率:对法国 39 家医院临床数据库的描述性分析。
Joint Bone Spine. 2022 Nov;89(6):105450. doi: 10.1016/j.jbspin.2022.105450. Epub 2022 Aug 6.

引用本文的文献

1
Aortic floating thrombus in patients with COVID-19: a report of eight cases.新型冠状病毒肺炎患者的主动脉漂浮血栓:8例报告
Gen Thorac Cardiovasc Surg. 2025 Mar;73(3):164-170. doi: 10.1007/s11748-024-02072-4. Epub 2024 Aug 14.
2
A Novel Percutaneous Technique for Aorto-Iliac Thrombectomy without the Risk of Embolization.一种新型的经皮主动脉-髂动脉血栓切除术,无栓塞风险。
Bioengineering (Basel). 2023 Jun 29;10(7):778. doi: 10.3390/bioengineering10070778.
3
Aortic thrombosis as a dramatic vascular complication in COVID-19 disease.

本文引用的文献

1
Editor's Choice - Update of the European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia in Light of the COVID-19 Pandemic, Based on a Scoping Review of the Literature.编辑精选 - 鉴于 COVID-19 大流行,基于文献范围综述对 2020 年欧洲血管外科学会(ESVS)急性肢体缺血管理临床实践指南的更新
Eur J Vasc Endovasc Surg. 2022 Jan;63(1):80-89. doi: 10.1016/j.ejvs.2021.08.028. Epub 2021 Sep 6.
2
Anticoagulation Before Hospitalization Is a Potential Protective Factor for COVID-19: Insight From a French Multicenter Cohort Study.抗凝治疗是 COVID-19 的潜在保护因素:一项法国多中心队列研究的启示
J Am Heart Assoc. 2021 Apr 20;10(8):e018624. doi: 10.1161/JAHA.120.018624. Epub 2021 Feb 8.
3
COVID-19 疾病中的主动脉血栓形成:一种戏剧性的血管并发症。
J Med Vasc. 2022 Oct;47(4):169-174. doi: 10.1016/j.jdmv.2022.10.003. Epub 2022 Oct 11.
Coronavirus Disease 2019-Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management.新型冠状病毒病相关血栓形成和凝血障碍:病理生理学特征综述及其对抗血栓治疗管理的影响。
J Am Heart Assoc. 2021 Feb 2;10(3):e019650. doi: 10.1161/JAHA.120.019650. Epub 2020 Nov 24.
4
Diagnosis, Management, and Pathophysiology of Arterial and Venous Thrombosis in COVID-19.新型冠状病毒肺炎中动脉和静脉血栓形成的诊断、管理及病理生理学
JAMA. 2020 Dec 22;324(24):2548-2549. doi: 10.1001/jama.2020.23422.
5
Thrombotic complications of COVID-19.COVID-19 的血栓并发症。
Am J Emerg Med. 2021 Jan;39:213-218. doi: 10.1016/j.ajem.2020.09.065. Epub 2020 Oct 1.
6
Patients with Initial Negative RT-PCR and Typical Imaging of COVID-19: Clinical Implications.初始RT-PCR检测阴性但具有典型COVID-19影像学表现的患者:临床意义。
J Clin Med. 2020 Sep 18;9(9):3014. doi: 10.3390/jcm9093014.
7
The coagulopathy, endotheliopathy, and vasculitis of COVID-19.COVID-19 的凝血功能障碍、血管内皮功能障碍和血管炎。
Inflamm Res. 2020 Dec;69(12):1181-1189. doi: 10.1007/s00011-020-01401-6. Epub 2020 Sep 12.
8
Acute Aortic Thrombosis Revealing a COVID-19 Infection.急性主动脉血栓形成揭示了新型冠状病毒肺炎感染
Eur J Vasc Endovasc Surg. 2020 Dec;60(6):827. doi: 10.1016/j.ejvs.2020.07.003. Epub 2020 Jul 7.
9
Coagulation Abnormalities and Thrombosis in Patients Infected With SARS-CoV-2 and Other Pandemic Viruses.新型冠状病毒和其他大流行病毒感染患者的凝血异常和血栓形成。
Arterioscler Thromb Vasc Biol. 2020 Sep;40(9):2033-2044. doi: 10.1161/ATVBAHA.120.314514. Epub 2020 Jul 13.
10
COVID-19-associated coagulopathy: An exploration of mechanisms.COVID-19 相关凝血功能障碍:机制探索。
Vasc Med. 2020 Oct;25(5):471-478. doi: 10.1177/1358863X20932640. Epub 2020 Jun 19.